Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers

Cancer Immunology, Immunotherapy

Volumn 59, Issue 12, 2010, Pages 1877-1884

  Geller, Melissa A ^a   Cooley, Sarah ^b   Argenta, Peter A ^a   Downs, Levi S ^a   Carson, Linda F ^a   Judson, Patricia L ^a   Ghebre, Rahel ^a   Weigel, Brenda ^b   Panoskaltsis Mortari, Angela ^b   Curtsinger, Julie ^c   Miller, Jeffrey S ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

852A; Breast cancer; Cervix cancer; Ovarian cancer; TLR 7 agonist

Indexed keywords

852A; ALTRETAMINE; ANTHRACYCLINE; BRAIN NATRIURETIC PEPTIDE; CARBOPLATIN; D DIMER; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GEMCITABINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; OXALIPLATIN; PACLITAXEL; PLATINUM DERIVATIVE; TOLL LIKE RECEPTOR AGONIST; TOPOTECAN; TROPONIN; UNCLASSIFIED DRUG; AMINOQUINOLINE DERIVATIVE; ANTINEOPLASTIC AGENT; N-(4-(4-AMINO-2-ETHYL-1H-IMIDAZO(4,5C)QUINOLIN-1-YL)BUTYL)METHANESULFONAMIDE; QUINOLINE DERIVATIVE; SULFONAMIDE; TLR7 PROTEIN, HUMAN; TOLL LIKE RECEPTOR 7;

ADJUVANT THERAPY; ADULT; AGED; ANOREXIA; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEHYDRATION; DIARRHEA; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG SELF ADMINISTRATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FEMALE; HEART EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INFECTION; KIDNEY FAILURE; LIVER METASTASIS; LIVER TOXICITY; MALAISE; MASTECTOMY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEPHROTOXICITY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT; OVARY CANCER; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECURRENT CANCER; RISK BENEFIT ANALYSIS; SIDE EFFECT; SINUS TACHYCARDIA; SPINE METASTASIS; SWEATING; THORAX PAIN; TREATMENT DURATION; TREATMENT FAILURE; UTERINE CERVIX CANCER; VOMITING; AGONISTS; BREAST NEOPLASMS; DRUG ADMINISTRATION; IMMUNOLOGY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PROSPECTIVE STUDY; SUBCUTANEOUS DRUG ADMINISTRATION; UTERINE CERVICAL NEOPLASMS;

ADULT; AGED; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PROSPECTIVE STUDIES; SULFONAMIDES; TOLL-LIKE RECEPTOR 7; UTERINE CERVICAL NEOPLASMS; QUINOLINES;

EID: 77957659880     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-010-0914-1     Document Type: Article

References (22)

1. AM Krieg 2002 CpG motifs in bacterial DNA and their immune effects Annu Rev Immunol 20 709 760 1:CAS:528:DC%2BD38XjtlWgtbw%3D 10.1146/annurev.immunol. 20.100301.064842 11861616 (Pubitemid 34293438)
2. I Kokkinopoulos WJ Jordan MA Ritter 2005 Toll-like receptor mRNA expression patterns in human dendritic cells and monocytes Mol Immunol 42 957 968 1:CAS:528:DC%2BD2MXjtFOmtrY%3D 10.1016/j.molimm.2004.09.037 15829287 (Pubitemid 40489021)
3. RL Miller JF Gerster ML Owens, et al. 1999 Imiquimod applied topically: a novel immune response modifier and new class of drug Int J Immunopharmacol 21 1 14 1:CAS:528:DyaK1MXitFyqtLk%3D 10.1016/S0192-0561(98)00068-X 10411278 (Pubitemid 29097684)
4. M Chen BP Griffith HL Lucia GD Hsiung 1988 Efficacy of S26308 against guinea pig cytomegalovirus infection Antimicrob Agents Chemother 32 678 683 1:CAS:528:DyaL1cXktFKlsb4%3D 2840014
5. DI Bernstein CJ Harrison MA Tomai RL Miller 2001 Daily or weekly therapy with resiquimod (R-848) reduces genital recurrences in herpes simplex virus-infected guinea pigs during and after treatment J Infect Dis 183 844 849 1:CAS:528:DC%2BD3MXisV2kur4%3D 10.1086/319262 11237799 (Pubitemid 32207051)
6. H Hemmi T Kaisho O Takeuchi, et al. 2002 Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway Nat Immunol 3 196 200 1:CAS:528:DC%2BD38XhtVygurc%3D 10.1038/ni758 11812998 (Pubitemid 34141451)
7. J Wenzel M Uerlich O Haller, et al. 2005 Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod J Cutan Pathol 32 257 262 10.1111/j.0303-6987.2005.00297.x 15769273 (Pubitemid 40459926)
8. T Meyer I Nindl T Schmook, et al. 2003 Induction of apoptosis by Toll-like receptor-7 agonist in tissue cultures Br J Dermatol 149 Suppl 66 9 14 1:CAS:528:DC%2BD2cXmtl2ntg%3D%3D 10.1046/j.0366-077X.2003.05632.x 14616338
9. AZYC Dudek LI Harrison S Kumar R Hawkinson, et al. 2007 First in human phase I trial of 852A, a novel systemic Toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer Clin Cancer Res 13 7119 7125 1:CAS:528:DC%2BD2sXhtlyitL3P 10.1158/1078-0432.CCR-07-1443 18056192 (Pubitemid 350276897)
10. LI Harrison C Astry S Kumar C Yunis 2007 Pharmacokinetics of 852A, an imidazoquinoline Toll-like receptor 7-specific agonist, following intravenous, subcutaneous, and oral administrations in humans J Clin Pharmacol 47 962 969 1:CAS:528:DC%2BD2sXps1Sjtbk%3D 10.1177/0091270007303766 17660481 (Pubitemid 47094102)
11. M Schiller D Metze TA Luger, et al. 2006 Immune response modifiers-mode of action Exp Dermatol 15 331 341 1:CAS:528:DC%2BD28Xltlaqtro%3D 10.1111/j.0906-6705.2006.00414.x 16630072 (Pubitemid 44056479)
12. KB Gorden KS Gorski SJ Gibson, et al. 2005 Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8 J Immunol 174 1259 1268 1:CAS:528:DC%2BD2MXlsFyhsQ%3D%3D 15661881
13. V Gangur FE Simons KT Hayglass 1998 Human IP-10 selectively promotes dominance of polyclonally activated and environmental antigen-driven IFN-gamma over IL-4 responses Faseb J 12 705 713 1:CAS:528:DyaK1cXjsVymsbo%3D 9619449 (Pubitemid 28247149)
14. H Yoneyama S Narumi Y Zhang, et al. 2002 Pivotal role of dendritic cell-derived CXCL10 in the retention of T helper cell 1 lymphocytes in secondary lymph nodes J Exp Med 195 1257 1266 1:CAS:528:DC%2BD38XjvFegt7g%3D 10.1084/jem.20011983 12021306 (Pubitemid 34564328)
15. K Schroder PJ Hertzog T Ravasi DA Hume 2004 Interferon-gamma: an overview of signals, mechanisms and functions J Leukoc Biol 75 163 189 1:CAS:528:DC%2BD2cXhsFKntrk%3D 10.1189/jlb.0603252 14525967 (Pubitemid 38174573)
16. DD Taub TJ Sayers CR Carter JR Ortaldo 1995 Alpha and beta chemokines induce NK cell migration and enhance NK-mediated cytolysis J Immunol 155 3877 3888 1:CAS:528:DyaK2MXos1KksLk%3D 7561094
17. ML Disis 2002 Immunologic targets for breast cancer Breast Dis 15 83 90 1:CAS:528:DC%2BD3sXislyiurY%3D 15687648
18. UR Hengge S Roth A Tannapfel 2005 Topical imiquimod to treat recurrent breast cancer Breast Cancer Res Treat 94 93 94 10.1007/s10549-005-7017-2 16172790 (Pubitemid 41416946)
19. M Adams H Navabi D Croston, et al. 2005 The rationale for combined chemo/immunotherapy using a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced ovarian cancer Vaccine 23 2374 2378 1:CAS:528:DC%2BD2MXitVCgtLg%3D 10.1016/j.vaccine.2005.04.017 15755631 (Pubitemid 40967980)
20. C Diaz-Arrastia I Arany SC Robazetti, et al. 2001 Clinical and molecular responses in high-grade intraepithelial neoplasia treated with topical imiquimod 5% Clin Cancer Res 7 3031 3033 1:CAS:528:DC%2BD3MXnvF2kurs%3D 11595691
21. R Dummer A Hauschild JC Becker, et al. 2008 An exploratory study of systemic administration of the Toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma Clin Cancer Res 14 856 864 1:CAS:528:DC%2BD1cXhsFyktLw%3D 10.1158/1078-0432.CCR-07-1938 18245549 (Pubitemid 351231170)
22. P Bonomi JA Blessing FB Stehman, et al. 1985 Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study J Clin Oncol 3 1079 1085 1:STN:280:DyaL2M3mtlOmsg%3D%3D 3894589